Bevacizumab biosimilar (Chia-tai Tianqing)

Primary objective To evaluate the safety and tolerability of TQB2922 for injection in subjects with advanced malignant tumors, and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) (if any); Secondary objective To evaluate the pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics, preliminary efficacy and immunogenicity of TQB2922 for injection in subjects with advanced malignant tumors.

Primary objective: To evaluate the pharmacokinetic (PK) similarity of bevacizumab injection produced by the new and old processes of Nanjing Shunxin Pharmaceutical Co., Ltd. of Chia Tai Tianqing Pharmaceutical Group in healthy male subjects after a single intravenous administration. Secondary objective: To evaluate the safety, tolerability and immunogenicity of bevacizumab injection produced by the new and old processes of Nanjing Shunxin Pharmaceutical Co., Ltd. of Chia Tai Tianqing Pharmaceutical Group in healthy male subjects after a single intravenous administration.